pgrn

SORT-PGRN interaction inhibitor 1 is a potent inhibitor of the sortilin-progranulin interaction, with an IC50 of 2 μM.

SORT-PGRN Interaction Inhibitor 3 (Compound 13), with an IC50 value of 0.17 μM, acts as an inhibitor of the SORT-PGRN interaction, and is utilized in the study of neurodegenerative diseases [1].

SORT-PGRN Interaction Inhibitor 2 is a compound that downregulates SORT1 protein expression and enhances extracellular progranulin (PGRN) secretion in various mammalian cell lines, and is utilized in the study of neurological diseases [1].

Ezeprogind (AZP2006), a lysotropic molecule associated with PGRN production, binds to PSAP (the cofactor of PGRN) and inhibits TLR9 receptors, which are normally responsible for proinflammation when activated. Ezeprogind has been used in Alzheimer's disease research.

Latozinemab (AL001) is a potent and selective recombinant humanized monoclonal antibody against Sortilin.Latozinemab has a high affinity for Sortilin and interrupts the interaction between the granule protein precursor (PGRN) and the Sortilin receptor.Latozinemab can be used to study of dementia and Alzheimer's disease.

BVFP is a PGRN-SORT1 inhibitor SORT1 antagonist that binds to key residues 588-593 of PGRN, a multifunctional secreted glycoprotein, and SORT1, a neuronal receptor for PGRN.BVFP is able to block PGRN-SORT1 binding, restore extracellular levels of PGRN , inhibits SORT1-mediated rPGRN endocytosis, and has therapeutic potential for frontotemporal lobe dementia (FTLD-TDP).

Progranulin Modulator-1 (Compound 60) is an orally active compound that promotes progranulin (PGRN) secretion. It enhances the ability of BV-2 cells to elevate PGRN levels, exhibits low cytotoxicity, and possesses an inhibitory effect on hERG. The EC50 for PGRN is 83 nM, and the IC50 for hERG is 3100 nM [1].

Progranulin modulator-3 (compd C40) is an orally active inducer of the precursor granulin protein (PGRN) that can penetrate the blood-brain barrier. It is utilized in neurological research.